KMT2C and myelodysplastic syndrome: In contrast, MLL3 (KMT2C), which is frequently lost in myelodysplastic syndrome (MDS), AML, aggressive nasopharyngeal carcinoma, and CRC, acts as a myeloma inhibitor that suppresses the self-renewal of hematopoietic stem cells and engages in differentiation via IL-1 stimulation72.